Sapropterin has recently been approved to treat hyperphenylalaninaemia in patients over 4 year-old with tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU) and in children and adults with BH4 deficiency.1 The effectiveness of this treatment in BH4-responsive PKU patients has already been demonstrated in randomized, double-blind trials; 2 moreover, Sapropterin appears well tolerated in PKU patients. It is thus the first non-dietary treatment for patients with PKU demonstrated capable of lowering blood phenylalanine levels, and as a result, it is a promising treatment option for BH4 responsive PKU patients. Yet there are still many open questions related to this treatment. One such question concerns how a positive responsiveness to BH4 is defined. Generally, a positive response is established when the baseline level of blood phenylalanine (Phe) decreases at least 30% after a BH4 load, but the practice of this particular loading test differs widely among different countries. The second question concerns the long-term usage, i.e. no long term tolerability data was available before. Finally, the issue regarding its usage in children less than 4 year-old and in maternal PKU patients remained to be addressed.